Annual EBITDA
-$393.42 M
-$19.26 M-5.15%
December 31, 2024
Summary
- As of March 1, 2025, RLAY annual EBITDA is -$393.42 million, with the most recent change of -$19.26 million (-5.15%) on December 31, 2024.
- During the last 3 years, RLAY annual EBITDA has fallen by -$170.33 million (-76.35%).
- RLAY annual EBITDA is now -724.17% below its all-time high of -$47.73 million, reached on December 31, 2018.
Performance
RLAY EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
-$83.64 M
+$11.36 M+11.95%
December 31, 2024
Summary
- As of March 1, 2025, RLAY quarterly EBITDA is -$83.64 million, with the most recent change of +$11.36 million (+11.95%) on December 31, 2024.
- Over the past year, RLAY quarterly EBITDA has increased by +$27.12 million (+24.48%).
- RLAY quarterly EBITDA is now -332.99% below its all-time high of $35.90 million, reached on December 31, 2020.
Performance
RLAY Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
-$380.21 M
+$9.24 M+2.37%
December 31, 2024
Summary
- As of March 1, 2025, RLAY TTM EBITDA is -$380.21 million, with the most recent change of +$9.24 million (+2.37%) on December 31, 2024.
- Over the past year, RLAY TTM EBITDA has dropped by -$12.35 million (-3.36%).
- RLAY TTM EBITDA is now -2316.33% below its all-time high of -$15.73 million, reached on March 31, 2019.
Performance
RLAY TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
RLAY EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -5.2% | +24.5% | -3.4% |
| 3 y3 years | -76.3% | -27.0% | -70.4% |
| 5 y5 years | -384.5% | -234.8% | -368.2% |
RLAY EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -76.3% | at low | -27.0% | +24.5% | -70.4% | +2.4% |
| 5 y | 5-year | -653.0% | at low | -333.0% | +24.5% | -627.7% | +2.4% |
| alltime | all time | -724.2% | at low | -333.0% | +24.5% | -2316.3% | +2.4% |
Relay Therapeutics EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2024 | -$393.42 M(+5.1%) | -$83.64 M(-12.0%) | -$380.21 M(-2.4%) |
| Sep 2024 | - | -$95.00 M(-14.2%) | -$389.45 M(+5.9%) |
| Jun 2024 | - | -$110.76 M(+22.0%) | -$367.87 M(+1.1%) |
| Mar 2024 | - | -$90.80 M(-2.2%) | -$363.97 M(-2.7%) |
| Dec 2023 | -$374.15 M(+21.9%) | -$92.89 M(+26.5%) | -$374.15 M(+2.9%) |
| Sep 2023 | - | -$73.41 M(-31.3%) | -$363.49 M(-2.2%) |
| Jun 2023 | - | -$106.87 M(+5.8%) | -$371.68 M(+8.8%) |
| Mar 2023 | - | -$100.98 M(+22.8%) | -$341.46 M(+11.3%) |
| Dec 2022 | -$306.82 M(+37.5%) | -$82.23 M(+0.8%) | -$306.82 M(+5.6%) |
| Sep 2022 | - | -$81.60 M(+6.4%) | -$290.45 M(+8.9%) |
| Jun 2022 | - | -$76.66 M(+15.5%) | -$266.83 M(+7.6%) |
| Mar 2022 | - | -$66.34 M(+0.7%) | -$247.94 M(+11.1%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2021 | -$223.08 M(+327.0%) | -$65.85 M(+13.6%) | -$223.08 M(+83.9%) |
| Sep 2021 | - | -$57.98 M(+0.4%) | -$121.33 M(+22.5%) |
| Jun 2021 | - | -$57.77 M(+39.2%) | -$99.05 M(+45.4%) |
| Mar 2021 | - | -$41.49 M(-215.6%) | -$68.13 M(+30.4%) |
| Dec 2020 | -$52.25 M(-35.7%) | $35.90 M(-200.6%) | -$52.25 M(-53.8%) |
| Sep 2020 | - | -$35.69 M(+32.9%) | -$113.13 M(+14.6%) |
| Jun 2020 | - | -$26.85 M(+4.9%) | -$98.71 M(+8.4%) |
| Mar 2020 | - | -$25.60 M(+2.5%) | -$91.07 M(+12.1%) |
| Dec 2019 | -$81.20 M(+70.1%) | -$24.98 M(+17.4%) | -$81.20 M(+44.4%) |
| Sep 2019 | - | -$21.27 M(+10.7%) | -$56.22 M(+60.9%) |
| Jun 2019 | - | -$19.21 M(+22.1%) | -$34.95 M(+122.1%) |
| Mar 2019 | - | -$15.73 M | -$15.73 M |
| Dec 2018 | -$47.73 M | - | - |
FAQ
- What is Relay Therapeutics annual EBITDA?
- What is the all time high annual EBITDA for Relay Therapeutics?
- What is Relay Therapeutics annual EBITDA year-on-year change?
- What is Relay Therapeutics quarterly EBITDA?
- What is the all time high quarterly EBITDA for Relay Therapeutics?
- What is Relay Therapeutics quarterly EBITDA year-on-year change?
- What is Relay Therapeutics TTM EBITDA?
- What is the all time high TTM EBITDA for Relay Therapeutics?
- What is Relay Therapeutics TTM EBITDA year-on-year change?
What is Relay Therapeutics annual EBITDA?
The current annual EBITDA of RLAY is -$393.42 M
What is the all time high annual EBITDA for Relay Therapeutics?
Relay Therapeutics all-time high annual EBITDA is -$47.73 M
What is Relay Therapeutics annual EBITDA year-on-year change?
Over the past year, RLAY annual EBITDA has changed by -$19.26 M (-5.15%)
What is Relay Therapeutics quarterly EBITDA?
The current quarterly EBITDA of RLAY is -$83.64 M
What is the all time high quarterly EBITDA for Relay Therapeutics?
Relay Therapeutics all-time high quarterly EBITDA is $35.90 M
What is Relay Therapeutics quarterly EBITDA year-on-year change?
Over the past year, RLAY quarterly EBITDA has changed by +$27.12 M (+24.48%)
What is Relay Therapeutics TTM EBITDA?
The current TTM EBITDA of RLAY is -$380.21 M
What is the all time high TTM EBITDA for Relay Therapeutics?
Relay Therapeutics all-time high TTM EBITDA is -$15.73 M
What is Relay Therapeutics TTM EBITDA year-on-year change?
Over the past year, RLAY TTM EBITDA has changed by -$12.35 M (-3.36%)